SG11201900043TA - Antibody formulations - Google Patents
Antibody formulationsInfo
- Publication number
- SG11201900043TA SG11201900043TA SG11201900043TA SG11201900043TA SG11201900043TA SG 11201900043T A SG11201900043T A SG 11201900043TA SG 11201900043T A SG11201900043T A SG 11201900043TA SG 11201900043T A SG11201900043T A SG 11201900043TA SG 11201900043T A SG11201900043T A SG 11201900043TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- sanofi
- main
- gmbh
- frankfurt
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- 235000020061 kirsch Nutrition 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662358404P | 2016-07-05 | 2016-07-05 | |
| EP16306090 | 2016-08-30 | ||
| PCT/EP2017/066803 WO2018007456A1 (en) | 2016-07-05 | 2017-07-05 | Antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900043TA true SG11201900043TA (en) | 2019-02-27 |
Family
ID=59325287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900043TA SG11201900043TA (en) | 2016-07-05 | 2017-07-05 | Antibody formulations |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11207407B2 (zh) |
| EP (1) | EP3481420A1 (zh) |
| JP (1) | JP7028855B2 (zh) |
| KR (3) | KR20240073999A (zh) |
| CN (2) | CN109661240B (zh) |
| AU (2) | AU2017293103B2 (zh) |
| BR (1) | BR112019000135A2 (zh) |
| CA (1) | CA3029642A1 (zh) |
| MX (1) | MX2019000177A (zh) |
| RU (1) | RU2769326C2 (zh) |
| SG (1) | SG11201900043TA (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113474360A (zh) | 2019-02-18 | 2021-10-01 | 伊莱利利公司 | 治疗性抗体制剂 |
| MX2022005317A (es) * | 2019-11-15 | 2022-05-26 | Hoffmann La Roche | Prevencion de formacion de particulas visibles en soluciones acuosas de proteina. |
| WO2023010483A1 (en) * | 2021-08-05 | 2023-02-09 | Hifibio (Hk) Limited | Anti-human cxcr5 antibody and uses thereof |
| EP4153130A1 (en) * | 2020-05-19 | 2023-03-29 | F. Hoffmann-La Roche AG | The use of chelators for the prevention of visible particle formation in parenteral protein solutions |
| EP4008345A1 (en) * | 2020-12-03 | 2022-06-08 | Hexal AG | Novel formulations for antibodies |
| CN117004700A (zh) * | 2023-10-07 | 2023-11-07 | 北京爱博生生物技术有限公司 | 单克隆抗体可变区基因高通量测序的方法及其所用组合物与试剂盒 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX346172B (es) | 2007-08-29 | 2017-03-10 | Sanofi - Aventis | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| CA3123252C (en) | 2012-03-26 | 2023-08-22 | Sanofi | Stable anti-cxcr5 igg4 antibody formulations |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
-
2017
- 2017-07-05 KR KR1020247015731A patent/KR20240073999A/ko not_active Application Discontinuation
- 2017-07-05 RU RU2019102943A patent/RU2769326C2/ru active
- 2017-07-05 BR BR112019000135-2A patent/BR112019000135A2/pt unknown
- 2017-07-05 JP JP2019500292A patent/JP7028855B2/ja active Active
- 2017-07-05 SG SG11201900043TA patent/SG11201900043TA/en unknown
- 2017-07-05 KR KR1020197003282A patent/KR102450280B1/ko active IP Right Grant
- 2017-07-05 EP EP17739230.5A patent/EP3481420A1/en active Pending
- 2017-07-05 CN CN201780054061.8A patent/CN109661240B/zh active Active
- 2017-07-05 US US16/315,533 patent/US11207407B2/en active Active
- 2017-07-05 CA CA3029642A patent/CA3029642A1/en active Pending
- 2017-07-05 KR KR1020227033547A patent/KR20220137159A/ko not_active IP Right Cessation
- 2017-07-05 CN CN202211433782.9A patent/CN115998858A/zh active Pending
- 2017-07-05 MX MX2019000177A patent/MX2019000177A/es unknown
- 2017-07-05 AU AU2017293103A patent/AU2017293103B2/en active Active
-
2021
- 2021-12-27 US US17/562,480 patent/US20220111048A1/en active Pending
-
2024
- 2024-09-19 AU AU2024219890A patent/AU2024219890A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220111048A1 (en) | 2022-04-14 |
| KR20220137159A (ko) | 2022-10-11 |
| JP2019520390A (ja) | 2019-07-18 |
| MX2019000177A (es) | 2019-06-20 |
| AU2017293103B2 (en) | 2024-08-15 |
| BR112019000135A2 (pt) | 2019-04-16 |
| KR20240073999A (ko) | 2024-05-27 |
| KR102450280B1 (ko) | 2022-10-04 |
| CN109661240A (zh) | 2019-04-19 |
| CA3029642A1 (en) | 2018-01-11 |
| JP7028855B2 (ja) | 2022-03-02 |
| RU2769326C2 (ru) | 2022-03-30 |
| RU2019102943A3 (zh) | 2020-11-11 |
| RU2019102943A (ru) | 2020-08-05 |
| CN109661240B (zh) | 2022-11-29 |
| KR20190027375A (ko) | 2019-03-14 |
| AU2024219890A1 (en) | 2024-10-10 |
| US11207407B2 (en) | 2021-12-28 |
| US20190255173A1 (en) | 2019-08-22 |
| EP3481420A1 (en) | 2019-05-15 |
| AU2017293103A1 (en) | 2019-02-21 |
| CN115998858A (zh) | 2023-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900043TA (en) | Antibody formulations | |
| SG11201907744QA (en) | Replacement of cytotoxic preconditioning before cellular immunotherapy | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201408261UA (en) | Syringe | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201810352XA (en) | New antibacterial compounds | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201809799WA (en) | Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201809474TA (en) | Compositions and methods for bioengineered tissues | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201408171SA (en) | Fbxo3 inhibitors | |
| SG11201809537VA (en) | Urea motif containing compounds and derivatives thereof as antibacterial drugs | |
| SG11201901320WA (en) | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS |